Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle

Himal Luitel1,*, Akylbek Sydykov1,*, Yves Schymura2,*, Argen Mamazhakypov1, Wiebke Janssen1,2, Kabita Pradhan1, Astrid Wietelmann3,*, Djuro Kosanovic1, Bhola Kumar Dahal1, Norbert Weissmann1, Werner Seeger1,2, Friedrich Grimminger1, Hossein Ardeschir Ghofrani1 & Ralph Theo Schermuly1

1 Excellence Cluster Cardio-Pulmonary System, Universities of Giessen and Marburg Lung Center, Member of the German Lung Center, Justus-Liebig-University Giessen, Giessen, Germany
2 Department of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
3 Max-Planck Institute for Heart and Lung Research, MRI Service Group, Bad Nauheim, Germany

Keywords
Mast cell, pulmonary artery banding, right ventricular hypertrophy.

Correspondence
Ralph Theo Schermuly, Universities of Giessen and Marburg Lung Center (UGMLC), Excellence Cluster Cardiopulmonary System (ECCPS), Aulweg 130, 35392 Giessen, Germany.
Tel: +496419942421
Fax: +496419942419
E-mail: ralph.schermuly@innere.med.uni-giessen.de

Funding Information
This work was supported by the DFG (German Research Foundation) grant SCHE 691/6-1, the CRC1213 (Collaborative Research Center 1213), the ECCPS (Excellence Cluster Cardiopulmonary System), Giessen and UGMLC (Universities of Giessen and Marburg Lung Center).

Received: 12 September 2016; Revised: 20 December 2016; Accepted: 9 January 2017
doi: 10.14814/phy2.13146

Physiol Rep, 5 (6), 2017, e13146, doi: 10.14814/phy2.13146

*Authors contributed equally.

Abstract
Right ventricular (RV) remodeling represents a complex set of functional and structural adaptations in response to chronic pressure or volume overload due to various inborn defects or acquired diseases and is an important determinant of patient outcome. However, the underlying molecular mechanisms remain elusive. We investigated the time course of structural and functional changes in the RV in the murine model of pressure overload-induced RV hypertrophy in C57Bl/6J mice. Using magnetic resonance imaging, we assessed the changes of RV structure and function at different time points for a period of 21 days. Pressure overload led to significant dilatation, cellular and chamber hypertrophy, myocardial fibrosis, and functional impairment of the RV. Progressive remodeling of the RV after pulmonary artery banding (PAB) in mice was associated with upregulation of myocardial gene markers of hypertrophy and fibrosis. Furthermore, remodeling of the RV was associated with accumulation and activation of mast cells in the RV tissue of PAB mice. Our data suggest possible involvement of mast cells in the RV remodeling process in response to pressure overload. Mast cells may thus represent an interesting target for the development of new therapeutic approaches directed specifically at the RV.

Introduction
Right ventricular (RV) remodeling represents a complex set of functional and structural adaptations induced by chronic pressure or volume overload due to various inborn defects or acquired diseases. Although the response of the RV to chronic pressure overload is an important determinant of patient outcome, the underlying molecular mechanisms remain elusive (Guarracino et al. 2005). A better understanding of the mechanisms of the RV remodeling may help identify candidate targets for novel therapeutic strategies directed specifically at the RV and thus improve...
survival in these patients. The availability of a murine model of pulmonary artery banding (PAB) provides us with a valuable tool to explore the mechanisms involved in the RV remodeling following pressure overload (Rockman et al. 1994; Tarnavski et al. 2004; Tarnavski 2009). Recently, a serial echocardiographic assessment of RV function changes in FVB mice subjected to PAB has been reported (Urashima et al. 2008). However, a more detailed investigation of longitudinal changes in concomitant mal-adaptive processes, including cardiomyocyte hypertrophy, myocardial fibrosis, and capillary density alterations, was not performed. In addition, numerous studies have demonstrated that significant differences in cardiac structure and function exist between mouse strains (Shah et al. 2010; Moreth et al. 2014). Even when cardiovascular parameters may not be different between strains under physiological conditions, genetic background may affect the cardiovascular response to various insults, such as hypoxia, aortic constriction, ischemia-reperfusion, or myocardial infarction (Campen et al. 2004; Gao et al. 2005; Barrick et al. 2007; Izikki et al. 2007; Tada et al. 2008; van den Borne et al. 2009; Barnabei et al. 2010). Moreover, strain-specific differences may affect results of pharmacological treatments (Lucki et al. 2001). Therefore, a direct comparison of findings of studies in which different inbred strains have been used may be challenging or impossible.

As recently shown in the rat SU/Hypoxia model of pulmonary arterial hypertension, differences in background strain can also affect the ability of the right heart to cope with increased pulmonary artery pressure (Jiang et al. 2016). However, the interstrain differences in the response of the RV to pressure overload have not been investigated comprehensively yet. Interestingly, it has recently been shown that C57BL/6J, the most widely used strain in the biomedical research (Simon et al. 2013), and FVB mice have different cardiovascular phenotypes at baseline and in response to acute hypoxic challenge (Barnabei et al. 2010). As a detailed characterization of the time course of pressure overload-induced changes in RV morphology and function in other commonly used mouse strains is still lacking, we sought to investigate serial changes in RV morphology and function in C57BL/6J mice subjected to sustained pressure overload. Although mast cell functions have been related to immune responses, a rapidly growing body of evidence has implicated these cells in a large variety of pathophysiological processes (Puxeddu et al. 2003). Mast cells are also present in the normal heart tissues in humans and animals (Marone et al. 2000) and an increasing number of studies suggest possible roles of cardiac mast cells in the pathogenesis of various cardiovascular diseases (Levick et al. 2011). In particular, enhanced accumulation of mast cells in hypertensive and failing left ventricles has been documented (Panizo et al. 1995; Shiota et al. 2003; Battle et al. 2006). Recent studies have identified important roles for mast cells in left ventricular hypertrophy and failure (Hara et al. 2002; Kitaura-Inenaga et al. 2003; Stewart et al. 2003). However, the role of mast cells in the development of RV hypertrophy is poorly understood. The goal of this study was therefore twofold. First, to better understand longitudinal changes in RV morphology and function in C57BL/6J mice subjected to sustained pressure overload. Second, to investigate the involvement of mast cells in the RV remodeling process.

Material and Methods

8–10-week-old male C57BL/6J mice (Charles River Laboratories, Sulzfeld, Germany) were maintained under appropriate barrier conditions in a 12-h/12-h light-dark cycle and received standard laboratory food ad libitum and free access to water. All procedures involving animals were approved by the governmental Animal Ethics Committee (Regierungspräsidium Darmstadt).

Model of PAB

Pressure overload was induced by PAB (n = 10 mice for each time point) as described (Kreyborg et al. 2010). Briefly, buprenorphine hydrochloride (0.05 mg/kg bw, Vetergesic, Braun) was administered s.c. as an analgesic prior to operation. Surgery was performed under general anesthesia using isoflurane (1.5–2.5% v/v). The animals were placed on a heating pad to maintain body temperature and were ventilated with a rodent ventilator (MiniVent Type 845, Hugo Sachs Elektronik KG, March, Germany). A lateral thoracotomy was performed to gain access to the pulmonary artery. The pulmonary artery was constricted to 350 μm using titanium clips (Hemoclip®, Weck, Germany) and a modified, adjustable clip applier (Hemoclip®). The chest and the skin incisions were closed by standard surgery techniques. Sham-operated mice (n = 10 mice for each time point) served as controls and underwent an identical procedure except for the placement of the clip around the pulmonary artery. Carprofen (8 mg/kg per day, Rimadyfl®, Pfizer) was administered via drinking water for 3 days post operation. Thereafter, animals were observed for various time periods after surgical procedures.

Magnetic resonance imaging

Cardiac magnetic resonance imaging (MRI) was performed at baseline (before surgery) and on postoperative days 3, 7, 14, and 21 (n = 10 mice per group for each time point). Mice were anesthetized by inhalation of isoflurane (2% v/v) in oxygen/medical air (0.5/0.5 L/min) mixture. Cardiac MR measurements were performed on a 7.0T Bruker
Perpendicular to the septum: LVEI length of the minor axis of left ventricle (L2), which runs parallel to the septum, to the left ventricle (L1), which runs orthogonally to the septum of both scout scans. Multiple views of the heart, followed by acquisition in axial view, were used to cover the ventricles. MRI data were analyzed using MASS4Mice digital imaging software (Medis, Leiden, Netherlands). The RV and left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV) were determined and based on these values stroke volume (SV) = EDV-ESV), ejection fraction (EF = (SV/EDV) *100%), and cardiac output (CO = SV × heart rate) were calculated automatically. The myocardial volume was determined as the area inside the epicardial border minus the endocardial area. The myocardial mass was then obtained by multiplying the myocardial volume and the density of myocardial tissue (1.05 g/mL). Left ventricular eccentricity index (LVEI) values were calculated for both end-diastole and end-systole in the axial plane at midpapillary level. It is calculated as the ratio of the length of the major axis of the left ventricle (L1), which runs parallel to the septum, to the length of the minor axis of left ventricle (L2), which runs perpendicular to the septum: LVEI = L1/L2.

**Hemodynamic measurements**

In vivo hemodynamic measurements were performed after completion of the protocols to induce RV hypertrophy (n = 10 mice per group for each time point). Mice were anesthetized using isoflurane (1.5% v/v) and placed on controlled heating and the core temperature, measured via rectal probe, was maintained at 37°C. The right jugular vein was used for catheterization of the RV to measure RV systolic pressure (RVSP), RV end-diastolic pressure (RVEDP), and time constant of isovolumic pressure decay Tau. Systemic arterial pressure (SAP) was measured by catheterizing the right carotid artery. Hemodynamic measurements were performed using a Millar microtip catheter (SPR-671, FMI, Foehr Medial Instruments GmbH, Secheim/Ober-Beerbach, Germany) and a PowerLab 8/30 System with the Chart 7.0 Software (AD Instruments GmbH, Spechbach, Germany).

**Tissue processing and histology**

 Hearts were harvested immediately after animals were killed (n = 5 mice per group for each time point). The ventricles were dissected free of the great vessels and atria. The RV was isolated from the left ventricle (LV) + septum (LV+S) by dissection along the septal insertion. The RV and (LV + S) were patted dry and weighed. The RV hypertrophy was assessed using the ratio of the RV mass to tibia length and to body weight.

Freshly dissected RV tissue was fixed in 4% paraformaldehyde overnight, then dehydrated and embedded in paraffin and sectioned at a thickness of 3 μm. To detect collagen fibers, RV sections were stained with 0.1% sirius red (sirius red F3B, Niepoetter, Bürstadt, Germany) in picric acid (Fluka, Neu-Ulm, Germany). For cardiomyocyte size determination transverse sections of the RV were stained with FITC conjugated wheat germ agglutinin (WGA-FITC, Sigma-Aldrich, Steinheim, Germany) for membrane staining. For quantification of the capillaries, sections were stained with IB4-TRITC (Sigma Aldrich). Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen, Karlsruhe, Germany) and mounted in DAKO fluorescence mounting medium (DAKO, Hamburg Germany). Sections without WGA-FITC, IB4-TRITC, and DAPI staining were used as a negative control. Photomicrographs were quantified to determine the mean cross-sectional area of cardiomyocytes and interstitial collagen fraction using Leica Qwin V3 computer-assisted image analysis software (Leica Microsystems, Wetzlar, Germany). Photomicrographs were quantified to count the number of cardiomyocytes and capillaries using STEFanizer image analysis tool (University of Bern, Department of Anatomy, Bern, Switzerland). Myocardial capillary density was expressed as a number of capillaries per cardiomyocyte. Average data reflect results from at least four or five different hearts in each group (more than 100 cells for each heart).

**Mast cell density and activity**

To identify mast cells, toluidine blue staining was performed using standard protocol (Dahal et al. 2011). Briefly, paraffin-embedded RV tissue sections were dewaxed, rehydrated and incubated with 0.05% w/v toluidine blue for 2–3 min. Mast cell density was quantified by counting the number of toluidine blue-positive cells from each entire RV longitudinal sections (Leica QWin, 200X) in two random sections. The mast cell density was expressed as a number of mast cells per mm². Degranulated mast cells are identified as cells in which granules are substantially reduced by 70–90% (Kanelakis et al. 2012). The results were expressed as percentage of degranulated mast cell to total amount of mast cells.

**Quantitative real-time PCR**

RV tissue samples were harvested immediately after mice were killed, snap-frozen in liquid nitrogen and stored at
Total mRNA was extracted from snap-frozen mouse RV tissue samples using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The primers used for real-time quantitative PCR are presented in the Table 1. All results were normalized to the relative expression of the constitutively expressed gene porphobilinogen deaminase (PBGD). The relative transcript abundance of the target gene is expressed in $\Delta C_t$ values ($\Delta C_t = C_t$ reference$–C_t$ target).

### Statistical analysis

Data are expressed as mean ± standard error the mean (SEM). All statistics were performed using GraphPad Prism software version 5.00 for Windows (GraphPad Software Inc., San Diego, CA). Differences between parameters of control and corresponding PAB mice at each time point were compared by an unpaired two-sided Student’s $t$-test or one-way ANOVA followed by Dunnett’s post hoc test. Differences in the time course of MRI parameters between sham and PAB mice were assessed using repeated measures ANOVA with Bonferroni post hoc test for multiple comparisons. Differences were considered statistically significant when $P < 0.05$.

### Results

In order to characterize the time course of morphological and functional changes in the RV in response to pressure overload, mice were randomly assigned to either sham or PAB group. Then a MRI analysis of the RV structure and function was performed at baseline before surgery and subsequently at 3, 7, 14, and 21 days after surgery.

Noninvasive MRI demonstrated that PAB led to severe dilatation, hypertrophy, and functional impairment of the RV (Fig. 1A–E). Pressure overload resulted in increased end-systolic and end-diastolic RV volumes on day 3 after PAB (Fig. 1A and B). The RV chamber dilatation was attenuated on postoperative day 7 but significantly increased afterwards. The RV dilatation was accompanied by impaired contractile function as reflected by decreased ejection fraction in PAB animals (Fig. 1C). In PAB mice, abnormal bulging of the interventricular septum toward the left ventricle due to compression exerted by dilated hypertrophied RV, as reflected by a rapid progressive increase in the LVEF both in systole and diastole (Fig. 1F and G), led to significant reduction in left ventricular end-systolic and end-diastolic volumes at all time points after surgery (Fig. 1H and I). The impaired ability of the left ventricle to properly dilate and fill resulted in reduced left ventricular stroke volume and cardiac output, whereas the left ventricular ejection fraction basically remained unchanged (Fig. 1J–L).

The RVSP in PAB mice increased with time coinciding with development of RV hypertrophy (Fig. 2A). The diastolic parameter Tau was elevated in PAB mice at all time points, whereas RVEDP started increasing from day 14 (Fig. 2B and C). The systemic blood pressure decreased slightly but significantly in PAB mice (Fig. 2D). The invasively determined RV hypertrophy developed rapidly after induction of pressure overload. The RV mass significantly increased in PAB mice as early as 3 days after surgery and continued to increase thereafter until day 21 (Fig. 2E and F). On a cellular level, significant cardiomyocyte hypertrophy was evident on day 7 after PAB and gradually increased thereafter (Fig. 2G and J). Significant interstitial collagen deposition in PAB mice occurred at day 7 after surgery and progressively increased over time (Fig. 2H and J). The number of microvessels per cardiomyocyte increased significantly by day 7 and remained elevated thereafter (Fig. 2I and J).
The RV remodeling process was associated with significantly increased mRNA expression levels of hypertrophic and profibrotic (ANP, BNP, collagen 1, collagen 3, Tgf-β, and PAI1) markers in RV tissue from PAB mice compared with those in the sham-operated control group. Expression of ANP and BNP mRNA increased early and was maintained at high levels up to 21 days after PAB (Fig. 3A and B). Interestingly, mRNA expression of profibrotic genes started increasing as early as 3 days after surgery, reached a maximum by day 7 and then gradually declined (Fig. 3C–F).

A time-dependent increase in total number of mast cells and the proportion of degranulated mast cells was detected in the remodeled RV tissue from PAB mice.
The proportion of degranulated mast cells started increasing from day 3 after PAB and reached a plateau by day 7. Remarkably, the mast cell density in PAB mice started increasing after 14 days and reached maximal values 21 days post surgery. The increased number of mast cells was accompanied by significantly increased mRNA expression of the mast cell marker c-Kit and mast cell-specific genes encoding murine mast cell proteases (mMCP)-2, 4, 5, and 6 in the RV at 7 and 14 days post surgery (Fig. 5A–F). Expression of the carboxypeptidase A3 (CPA3) increased early after PAB and remained elevated for the entire period (Fig. 5G). Similarly, augmented expression of the cytokine IL-6 was observed in RV tissue of PAB mice at all time points (Fig. 5H). Significantly elevated RV expression of TNF-alpha in PAB mice was noted at 7 and 14 days after PAB which further increased by day 21 (Fig. 5I).

Discussion

In this study, we characterized the longitudinal changes in RV morphology and function in response to pressure overload in C57BL/6J mice. We demonstrated that PAB led to significant dilatation, cellular and chamber hypertrophy, and functional impairment of the RV. Compression of the left ventricle exerted by dilated and hypertrophied RV caused flattening of the interventricular septum and was reflected by the increased LVEI. The latter has been shown to increase in various RV pressure and volume overload states (Ryan et al. 1985; Ascah et al. 1990; Louie et al. 1992). Due to deleterious interventricular interaction, compression of the left ventricle led to significant reduction in left ventricular end-systolic and end-diastolic volumes. The impaired ability of the left ventricle to properly dilate and fill resulted in reduced left...
ventricular stroke volume and cardiac output, whereas its contractile function remained unchanged. Progressive remodeling of the RV in PAB mice was associated with upregulation of myocardial gene markers of hypertrophy and fibrosis. Pressure overload of the RV may also lead to reduction in capillary density (Hudlicka et al. 1992), which may contribute to ventricular dysfunction. In contrast, our study demonstrated that number of capillaries per cardiomyocyte actually slightly increased in PAB mice as compared with sham mice. However, taking into account significant increase in cardiomyocyte size in PAB mice, blood supply to individual cardiomyocytes may remain reduced.

Although, pulmonary artery banding has recently become an important model of pressure overload induced RV hypertrophy and several research groups including our own have reported maladaptive alterations (Kreymborg et al. 2010; Kapur et al. 2013; Rajagopalan et al. 2013; Egennazarov et al. 2015; West et al. 2016), serial assessment of RV morphology and function in mice subjected to pressure overload of various degrees was performed only in one study, which utilized FVB mice (Urashima et al. 2008). In that study, severe pulmonary artery stenosis was associated with significant RV cardiomyocyte and chamber hypertrophy, RV dilatation and dysfunction, reduced cardiac output, and increased mortality. Although, we have not performed a direct comparison of FVB and C57Bl/6J mice, we think that the degree of pressure overload, RV hypertrophy, and dysfunction in C57Bl/6J mice was comparable with that of FVB mice with severe pulmonary artery constriction. Our findings suggest that compared with the FVB strain, C57Bl/6J mice subjected to severe RV pressure overload are not prone to increased mortality during the first 3 weeks. The cause for increased mortality in FVB mice is not clear as RV dysfunction did not decline with time but may be related to development of malignant arrhythmias. Unfortunately, a detailed characterization of longitudinal changes in concomitant maladaptive processes, including myocardial fibrosis and capillary density alterations, is lacking for FVB mice. Nevertheless, our findings suggest that interstrain differences can affect the ability of the RV to cope with sustained pressure overload.

Inflammatory activation contributes to the pathogenesis of both left ventricular (Sun et al. 2007; Coggins and Rosenzweig 2012) and RV adverse remodeling and dysfunction (Campion et al. 2010; Rondelet et al. 2012; Dewachter et al. 2015). Previous reports have shown that cardiac mast cells are a component of the inflammatory response in various models of adverse left ventricular remodeling (Levick et al. 2008, 2009; Zhang et al. 2011). Mast cells are cells of hematopoietic lineage residing in the tissues. In normal human and rodent hearts, the number of mast cells ranges between 1.5 and 5.3 cells/mm² (Rakusan et al. 1990; Patella et al. 1998). Enhanced accumulation of mast cells in left ventricular tissue from late-stage heart failure patients (194 ± 19.6 cells/cm² vs. 131 ± 22.2 cells/cm² in control ventricles) has been documented (Batlle et al. 2006). Interestingly, an increase in cardiac mast cell density of similar magnitude is reported in various animal models of left ventricular hypertrophy and failure. In the rat model of left ventricular
hypertrophy induced by transverse aortic constriction, the number of cardiac mast cells increased from about 2 cells/mm\(^2\) in sham animals to 3 cells/mm\(^2\) 5 weeks post surgery (Li et al. 2016). Comparable cardiac mast cell densities are reported in spontaneously hypertensive rats (Shiota et al. 2003). The temporal responses in the density of myocardial mast cells in the model of biventricular volume overload was similar for the left ventricle and RV (Brower et al. 2002). The number of mast cells in the RV at 21 days post fistula was 3.11 \(\pm\) 2.01 versus 2.34 \(\pm\) 1.00 cells/mm\(^2\) in the control. The issue of whether degranulation of this small number of cells is sufficient to cause ventricular remodeling has specifically been addressed in a study using isolated hearts, which findings clearly demonstrated that degranulation of mast cells present in normal hearts is sufficient to induce extracellular matrix degradation via activation of MMPs and produce alteration in ventricular function (Chancey et al. 2002). Importance of this small number of mast cells for cardiac remodeling is further supported by studies utilizing mast cell stabilizers, inhibitors of mast cell proteases and mast cell-deficient mice (Hara et al. 2002; Matsumoto et al. 2003; Levick et al. 2009; Liu et al. 2012). Given the role of mast cells in the hypertensive and failing left ventricle, we were interested, if mast cells are also involved in the RV remodeling. Earlier studies in rats have shown that prolonged duration (200 days) of pressure overload on the RV induced by PAB is associated with more than threefold increase in the mast cell density (Olivetti et al. 1989). In contrast, cardiac mast cell density was not affected in 3-month-old rats born at high altitude despite development of significant RV hypertrophy (Rakusan et al. 1990). However, it remains unclear, if this discrepancy is due to the differences in the duration of the overload or if it is model-dependent. In addition, temporal responses to pressure overload in the density of

Figure 5. Time course of the right ventricular mRNA gene expression analysis of genes related to mast cells (A–G) and inflammation (H and I) in sham and PAB mice. (A) c-Kit. (B) Murine mast cell protease (mMCP)-1. (C) mMCP2. (D) mMCP4. (E) mMCP5. (F) mMCP6. (G) carboxypeptidase-3 (CPA3). (H) IL-6. (I) TNF-\(\alpha\). Values are means \(\pm\) SEM. *\(p\) < 0.05 versus sham at corresponding time points, \(n = 5\) mice per group. PAB, pulmonary artery banding.
Mast cells in Right Ventricular Hypertrophy
H. Luitel et al.

cardiac mast cells has not been addressed yet. We investigated the number and activity of mast cells in RV tissue at different time points after PAB. We found an early activation of mast cells evidenced by an increase in the proportion of the degranulated mast cells in the RV tissue. In contrast, mast cell density started increasing after 2 weeks and reached maximal values 3 weeks post surgery. Interestingly, increased expression of c-Kit and soluble stem cell factor and enhanced cardiac mast cells density were observed in the prehypertensive spontaneously hypertensive rats even before any signs of cardiac hypertrophy or fibrosis (Shiota et al. 2003). An early elevation in mast cell density in both left and right ventricles was observed in a rat model of biventricular volume overload (Brower et al. 2002; Forman et al. 2006). In this model, the number of mast cells increased within 24 h and remained elevated for the first 5 days post-fistula before returning to normal values by day 14.

Increase in mast cell density can result from proliferation and maturation of immature resident mast cells (Forman et al. 2006; Li et al. 2012) as well as recruitment of mast cell progenitors from the bone marrow or white adipose tissue and further proliferation and maturation in the tissue (Frangogiannis et al. 1998; Ngkelo et al. 2016). Increased chymase activity secondary to mast cell activation may increase tissue levels of stem cell factor by cleaving membrane-bound stem cell factor to release a soluble form (Longley et al. 1997). Higher levels of the stem cell factor then rapidly elevate mast cell numbers by stimulating maturation of immature resident mast cells in the heart (Li et al. 2012). However, the mast cell density returns to normal values at 5–7 days post fistula (Brower et al. 2002; Forman et al. 2006). Thus, the increase in cardiac mast cell density in response to volume overload is due to maturation and differentiation, but not proliferation of a resident population of immature cardiac mast cells. Rather late increase in mast cell density in our experiments may be due to different underlying mechanisms. Indeed, recruitment of mast cell precursors and further maturation in the tissue requires a considerable amount of time (Jamur et al. 2010). In addition, interspecies differences (Halapas et al. 2008) and type of overload stress (Bartelds et al. 2011; Borgdorff et al. 2013) may account for this discrepancy. Nevertheless, this issue deserves further investigation.

Depending on the magnitude of the stimulus, activation mode and selective activation of specific signaling pathways, mast cells release unique arrays of preformed and newly synthesized biologically active substances (Rao and Brown 2008; Gilfillan et al. 2011). Potential mechanisms of the involvement of mast cells in the cardiac remodeling include stimulation of collagen synthesis leading to myocardial fibrosis or activation of matrix metalloproteinases resulting in collagen degradation and ventricular dilatation. Mast cells serve as a source of a number of cytokines, which are mitogenic and chemotactic for fibroblasts and stimulate production of extracellular matrix by fibroblasts. It has been demonstrated that cardiac mast cells participate in the induction of cardiac hypertrophy and cardiac fibrosis by synthesizing and secreting prohypertrophic cytokines and probiotic growth factors TGF-β and bFGF (Shiota et al. 2003). Moreover, cardiac mast cells can promote tissue fibrosis by stimulating cell proliferation and collagen expression in cardiac fibroblasts through PDGF-A (Liao et al. 2010). Mast cells also release both preformed and newly synthesized cytokines TNF-α and IL-6 (Gordon and Galli 1990, 1991; Gagari et al. 1997) which have previously been shown to mediate cardiac fibrosis and hypertrophy in various animal models (Sun et al. 2007; Melendez et al. 2010; Gonzalez et al. 2015; Sriramula and Francis 2015). Similar to the findings from the left ventricular hypertrophy studies, we found significantly elevated mRNA levels of TNF-α and IL-6 in RV tissues from PAB mice compared with those from sham mice suggesting their potential contribution to RV remodeling process. Besides cytokines, mast cell granules contain very high levels of a number of proteases and mast cell degranulation leads to release of active mast cell proteases (Stevens and Adachi 2007). Mouse mast cell consists of various proteases including chymases (mMCP-1, -2, -4, -5, -6, -9), tryptases (mMCP-6, -7, membrane-bound tryptase and a number of other trypsin-like serine proteases), and the exopeptidase CPA3 (Pejler et al. 2010). Mast cell chymases and tryptases are potent activators of fibroblast proliferation and inducers of matrix protein synthesis (Cairns and Walls 1997; Akers et al. 2000; Zhao et al. 2008; McLarty et al. 2011). Mast cells proteases can promote extracellular matrix accumulation through formation of angiotensin II (Uratani et al. 1990), activation of TGF-β (Lindstedt et al. 2001), or by acting as mitogens for fibroblasts (Ruos et al. 1991). Previous studies have demonstrated that expression and activity of mast cell proteases trypstat and chymase are elevated in the hypertensive left ventricles (Shiota et al. 1997; Li et al. 2002; Levick et al. 2009; Li et al. 2016). We performed analysis of gene expression in RV tissues from PAB mice and found a significant upregulation of several mouse mast cell proteases including mMcp-2, 4, 5, 6, and CPA3. Inhibition of mast cell chymase and tryptase has been shown to prevent cardiac fibrosis and improve left ventricular dysfunction in various left heart disease models (Matsumoto et al. 2003; Kanemitsu et al. 2006, 2008; Li et al. 2016). Interestingly, inhibition of mast cell chymase increases the cardiac efficacy of angiotensin I-converting enzyme inhibitor therapy and improves survival after myocardial infarction in
Mast cells in Right Ventricular Hypertrophy

hampsters (Jin et al. 2003; Wei et al. 2010). These data demonstrate that selective inhibition of mast cell proteases might represent an important strategy for management of cardiac dysfunction.

In summary, our work provided a detailed description of the longitudinal changes in RV morphology and function in response to pressure overload in C57BL/6J mice. We also demonstrated accumulation and activation of mast cells in the RV tissue of PAB mice. Our data suggest possible involvement of mast cells in the RV remodeling process in response to pressure overload. Mast cells may thus represent an interesting target for the development of new therapeutic approaches directed specifically at the RV.

Acknowledgments
We thank Ewa Bieniek and Christina Vroom for expert technical assistance.

Conflicts of Interest
No conflicts of interest, financial or otherwise, are declared by the author(s).

References
Akers, I. A., M. Parsons, M. R. Hill, M. D. Hollenberg, S. Sanjar, G. J. Laurent, et al. 2000. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol. Lung Cell. Mol. Physiol. 278:L193-L201.
Ascah, K. J., M. E. King, L. D. Gillam, and A. E. Weyman. 1990. The effects of right ventricular hemodynamics on left ventricular configuration. Can. J. Cardiol. 6:99–106.
Barnabei, M. S., N. J. Palpant, and J. M. Metzger. 2010. Influence of genetic background on ex vivo and in vivo cardiac function in several commonly used inbred mouse strains. Physiol. Genomics 42A:103–113.
Barrick, C. J., M. Rojas, R. Schoonhoven, S. S. Smyth, and D. W. Threadgill. 2007. Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 292:H2119–H2130.
Bartelds, B., M. A. Borgdorff, A. Smit-van Oosten, J. Takens, B. Boersma, M. G. Nederhoff, et al. 2011. Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. Eur. J. Heart Fail. 13:1275–1282.
Batlle, M., E. Roig, F. Perez-Villa, S. Lario, P. Cejudo-Martin, E. Garcia-Pras, et al. 2006. Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J. Heart Lung Transplant. 25:1117–1125.
Borgdorff, M. A., B. Bartelds, M. G. Dickinson, P. Steendijk, M. de Vroome, and R. M. Berger. 2013. Distinct loading conditions reveal various patterns of right ventricular adaptation. Am. J. Physiol. Heart Circ. Physiol. 305:H354–H364.
van den Borne, S. W., V. A. van de Schans, A. E. Strzelecka, H. T. Vervoort-Peters, P. M. Lijnen, J. P. Cleutjens, et al. 2009. Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc. Res. 84:273–282.
Brower, G. L., A. L. Chancey, S. Thanigajari, B. B. Matsumbara, and J. S. Janicki. 2002. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am. J. Physiol. Heart Circ. Physiol. 283:H518–H525.
Cairns, J. A., and A. F. Walls. 1997. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313–1321.
Campen, M. J., Y. Tagaito, J. Li, A. Balbir, C. G. Tankersley, P. Smith, et al. 2004. Phenotypic variation in cardiovascular responses to acute hypoxic and hypercapnic exposure in mice. Physiol. Genomics 20:15–20.
Campian, M. E., M. Hardziyenka, K. de Bruin, B. L. van Eck-Smit, J. M. de Bakker, H. J. Verberne, et al. 2010. Early inflammatory response during the development of right ventricular heart failure in a rat model. Eur. J. Heart Fail. 12:653–658.
Chancey, A. L., G. L. Brower, and J. S. Janicki. 2002. Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function. Am. J. Physiol. Heart Circ. Physiol. 282:H2152–H2158.
Coggins, M., and A. Rosenzweig. 2012. The fire within: cardiac inflammatory signaling in health and disease. Circ. Res. 110:116–125.
Dahal, B. K., D. Kosanovic, C. Kaulen, T. Cornitescu, R. Savai, J. Hoffmann, et al. 2011. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir. Rev. 12:60.
Dewachter, C., A. Belhaj, B. Rondelet, M. Vercruysse, D. P. Schraufnagel, M. Remmelink, et al. 2015. Myocardial inflammation in experimental acute right ventricular failure: Effects of prostacyclin therapy. J. Heart Lung Transplant. 34:1334–1345.
Egemenazarov, B., A. Schmidt, S. Crnkovic, A. Sydykov, B. M. Nagy, G. Kovacs, et al. 2015. Pressure overload creates right ventricular diastolic dysfunction in a mouse model: assessment by echocardiography. J. Am. Soc. Echocardiogr. 28:828–843.
Forman, M. F., G. L. Brower, and J. S. Janicki. 2006. Rat cardiac mast cell maturation and differentiation following acute ventricular volume overload. Inflamm. Res. 55:408–415.
Frangogiannis, N. G., J. L. Perrard, L. H. Mendoza, A. R. Burns, M. L. Lindsey, C. M. Ballantyne, et al. 1998. Stem
cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 98:687–698.
Gagari, E., M. Tsai, C. S. Lantz, L. G. Fox, and S. J. Galli. 1997. Differential release of mast cell interleukin-6 via c-kit. Blood 89:2654–2663.
Gao, X. M., Q. Xu, H. Kiriazis, A. M. Dart, and X. J. Du. 2005. Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovasc. Res. 65:469–477.
Giffillan, A. M., S. J. Austin, and D. D. Metcalfe. 2011. Mast cell biology: introduction and overview. Adv. Exp. Med. Biol. 716:2–12.
Gonzalez, G. E., N. E. Rhaleb, M. A. D’Ambrosio, P. Nakagawa, Y. Liu, P. Leung, et al. 2013. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J. Hypertens. 33:144–152.
Gordon, J. R., and S. J. Galli. 1990. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346:274–276.
Gordon, J. R., and S. J. Galli. 1991. Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J. Exp. Med. 174:103–107.
Guarracino, F., C. Cariello, A. Danella, L. Doroni, F. Lapolla, C. Vullo, et al. 2005. Right ventricular failure: physiology and assessment. Minerva Anestesiol. 71:307–312.
Halapas, A., A. Papalois, A. Stauropoulou, A. Philippou, N. Pissimissis, A. Chatzigeorgiou, et al. 2008. In vivo models for heart failure research. In Vivo 22:767–780.
Hara, M., K. Ono, M. W. Hwang, A. Iwasaki, M. Okada, K. Nakatani, et al. 2002. Evidence for a role of mast cells in the evolution to congestive heart failure. J. Exp. Med. 195:375–381.
Hudlicka, O., M. Brown, and S. Egginton. 1992. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 72:369–417.
Izikki, M., N. Hanoun, E. Marcos, L. Savale, A. M. Barlier-Mur, F. Saurini, et al. 2007. Tryptophan hydroxylation 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 293:L1045–L1052.
Jamur, M. C., A. N. Moreno, L. F. Mello, D. A. Souza Junior, M. R. Campos, M. V. Pastor, et al. 2010. Mast cell repopulation of the peritoneal cavity: contribution of mast cell progenitors versus bone marrow derived committed mast cell precursors. BMC Immunol. 11:32.
Jiang, B., Y. Deng, C. Suen, M. Taha, K. R. Chaudhary, D. W. Courtman, et al. 2016. Marked strain-specific differences in the S5416 rat model of severe pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 54:461–468.
Jin, D., S. Takai, M. Yamada, M. Sakaguchi, K. Kamoshita, K. Ishida, et al. 2003. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc. Res. 60:413–420.
Kanellakis, P., M. Dittatkovski, G. Kostolias, and A. Bobik. 2012. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc. Res. 95:77–85.
Kanemitsu, H., S. Takai, H. Tsuneyoshi, T. Nishina, K. Yoshikawa, M. Miyazaki, et al. 2006. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens. Res. 29:57–64.
Kanemitsu, H., S. Takai, H. Tsuneyoshi, E. Yoshikawa, T. Nishina, M. Miyazaki, et al. 2008. Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. Eur. J. Cardiothorac. Surg. 33:25–31.
Kapur, N. K., V. Paruchuri, M. J. Aronovitz, X. Qiao, E. E. Mackey, G. H. Daly, et al. 2013. Biventricular remodeling in murine models of right ventricular pressure overload. PLoS ONE 8:e70802.
Kitaura-Inenaga, K., M. Hara, K. Higuchi, K. Yamamoto, A. Yamaki, K. Ono, et al. 2003. Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. Circ. J. 67:881–884.
Kreyming, K., S. Uchida, P. Gellert, A. Schneider, T. Boettger, R. Voswinckel, et al. 2010. Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. J. Mol. Cell. Cardiol. 49:598–605.
Levick, S. P., J. D. Gardner, M. Holland, M. Hauer-Jensen, J. S. Janicki, and G. L. Brower. 2008. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J. Mol. Cell. Cardiol. 45:56–61.
Levick, S. P., J. L. McLarty, D. B. Murray, R. M. Freeman, W. E. Carver, and G. L. Brower. 2009. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53:1041–1047.
Levick, S. P., G. C. Melendez, E. Plante, J. L. McLarty, G. L. Brower, and J. S. Janicki. 2011. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc. Res. 89:12–19.
Li, P., P. M. Chen, S. W. Wang, and L. Y. Chen. 2002. Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload. Hypertens. Res. 25:757–762.
Li, J., H. Lu, E. Plante, G. C. Melendez, S. P. Levick, and J. S. Janicki. 2012. Stem cell factor is responsible for the rapid response in mature mast cell density in the acutely stressed heart. J. Mol. Cell. Cardiol. 53:469–474.
Li, J., S. Jubair, S. P. Levick, and J. S. Janicki. 2011. The autocrine role of tryptase in pressure overload-induced mast cell activation, chymase release and cardiac fibrosis. IJC Metab. Endocr. 10:16–23.
Liao, C. H., H. Akazawa, M. Tamagawa, K. Ito, N. Yasuda, and Y. Kudo, et al. 2010. Cardiac mast cells cause atrial
fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J. Clin. Invest. 120:242–253.

Lindstedt, K. A., Y. Wang, N. Shiota, J. Saarinen, M. Hyrytainen, J. O. Kokkonen, et al. 2001. Activation of paracrine TGF-beta signaling upon stimulation and degradation of rat serosal mast cells: a novel function for chymase. FASEB J. 15:1377–1388.

Liu, W., J. Chen, T. Xu, W. Tian, Y. Li, Z. Zhang, et al. 2012. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am. J. Hypertens. 25:250–260.

Longley, B. J., L. Tyrrell, Y. Ma, D. A. Williams, R. Halahan, K. Langley, et al. 1997. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc. Natl Acad. Sci. USA 94:9017–9021.

Louie, E. K., S. Rich, S. Levitsky, and B. H. Brundage. 1992. Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. J. Am. Coll. Cardiol. 19:84–90.

Lucki, I., A. Dalvi, and A. J. Mayorga. 2001. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155:315–322.

Marone, G., G. De Rescenzo, V. Patella, F. Granata, L. Verga, and E. Arbustini, et al. (2000). Human heart mast cells: immunological characterization in situ and in vitro. Pp. 455–477 in G. Marone, L. M. Lichtenstein, F. J. Galli. Mast cells and basophils. Academic Press, London, UK.

Matsumoto, T., A. Wada, T. Tsutamoto, M. Ohnishi, T. Isono, and M. Kinoshita. 2003. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107:2555–2558.

McLarry, J. L., G. C. Melendez, G. L. Brower, J. S. Janicki, and S. P. Levick. 2011. Tryptase/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension 58:264–270.

Melendez, G. C., J. L. McLarty, S. P. Levick, Y. Du, J. S. Janicki, and G. L. Brower. 2010. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56:225–231.

Moreth, K., R. Fischer, H. Fuchs, V. Gailius-Durner, W. Wurst, H. A. Katus, et al. 2014. High-throughput phenotypic assessment of cardiac physiology in four commonly used inbred mouse strains. J. Comp. Physiol. B. 184:763–775.

Ngkelo, A., A. Richart, J. A. Kirk, P. Bonnin, J. Vilar, M. Lemitre, et al. 2016. Mast cells regulate myoflament calcium sensitization and heart function after myocardial infarction. J. Exp. Med. 213:1353–1374.

Olivetti, G., C. Lagrasta, R. Ricci, E. H. Sonnenblick, J. M. Capasso, and P. Anversa. 1989. Long-term pressure-induced cardiac hypertrophy: capillary and mast cell proliferation. Am. J. Physiol. 257:H1766–H1772.

Panizo, A., F. J. Mindan, M. F. Galindo, E. Cenarruzabetia, M. Hernandez, and J. Diez. 1995. Are mast cells involved in hypertensive heart disease? J. Hypertens. 13:1201–1208.

Patella, V., I. Marino, E. Arbustini, B. Lamparter-Schummert, L. Verga, M. Adt, et al. 1998. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 97:971–978.

Pejler, G., E. Ronnberg, I. Waern, and S. Wernersson. 2010. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115:4981–4990.

Puxeddu, I., A. M. Piliponsky, I. Bachelet, and F. Levi-Schaffer. 2003. Mast cells in allergy and beyond. Int. J. Biochem. Cell Biol. 35:1601–1607.

Rajagopalan, V., M. Zhao, S. Reddy, G. Fajardo, X. Wang, S. Dewey, et al. 2013. Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure. Am. J. Physiol. Heart Circ. Physiol. 305:H551–H562.

Rakusan, K., K. Sarkar, Z. Turek, and P. Wicker. 1990. Mast cells in the rat heart during normal growth and in cardiac hypertrophy. Circ. Res. 66:511–516.

Rao, K. N., and M. A. Brown. 2008. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann. N. Y. Acad. Sci. 1143:83–104.

Rockman, H. A., S. Ono, R. S. Ross, L. R. Jones, M. Karimi, V. Bhargava, et al. 1994. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad. Sci. USA 91:2694–2698.

Rondelet, B., C. Dewachter, F. Kerbau, X. Kang, P. Fesler, S. Brimioulle, et al. 2012. Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure. Eur. Heart J. 33:1017–1026.

Ruoss, S. J., T. Hartmann, and G. H. Caughey. 1991. Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. 88:493–499.

Ryan, T., O. Petrovic, J. C. Dillon, H. Feigenbaum, M. J. Conley, and W. F. Armstrong. 1985. An echocardiographic index for separation of right ventricular volume and pressure overload. J. Am. Coll. Cardiol. 5:918–927.

Shah, A. P., U. Siedlecka, A. Gandhi, M. Navaratnarajah, S. A. Al-Saud, M. H. Yacoub, et al. 2010. Genetic background affects function and intracellular calcium regulation of mouse hearts. Cardiovasc. Res. 87:683–693.

Shiota, N., D. Jin, S. Takai, T. Kawamura, M. Koyama, N. Nakamura, et al. 1997. Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension. FEBS Lett. 406:301–304.

Shiota, N., J. Rysa, P. T. Kovanen, H. Ruskoaho, J. O. Kokkonen, and K. A. Lindstedt. 2003. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J. Hypertens. 21:1935–1944.

Simon, M. M., S. Greenaway, J. K. White, H. Fuchs, V. Gailius-Durner, S. Wells, et al. 2013. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 14:R82.
Sriramula, S., and J. Francis. 2015. Tumor Necrosis Factor - Alpha Is Essential for Angiotensin II-Induced Ventricular Remodeling: Role for Oxidative Stress. PLoS ONE 10: e0138372.

Stevens, R. L., and R. Adachi. 2007. Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunol. Rev. 217:155–167.

Stewart, J. A. Jr, C. C. Wei, G. L. Brower, P. E. Rynders, G. H. Hankes, A. R. Dillon, et al. 2003. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J. Mol. Cell. Cardiol. 35:311–319.

Sun, M., M. Chen, F. Dawood, U. Zurawska, J. Y. Li, T. Parker, et al. 2007. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115:1398–1407.

Tada, Y., S. Laudi, J. Harral, M. Carr, C. Ivester, N. Tanabe, et al. 2008. Murine pulmonary response to chronic hypoxia is strain specific. Exp. Lung Res. 34:313–323.

Tarnavski, O. 2009. Mouse surgical models in cardiovascular research. Methods Mol. Biol. 573:115–137.

Tarnavski, O., J. R. McMullen, M. Schinke, Q. Nie, S. Kong, and S. Izumo. 2004. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. Genomics 16:349–360.

Urashima, T., M. Zhao, R. Wagner, G. Fajardo, S. Farahani, T. Quertermous, et al. 2008. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am. J. Physiol. Heart Circ. Physiol. 295: H1351–H1368.

Urata, H., A. Kinoshita, K. S. Misono, F. M. Bumpus, and A. Husain. 1990. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265:22348–22357.

Wei, C. C., N. Hase, Y. Inoue, E. W. Bradley, E. Yahiro, M. Li, et al. 2010. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Invest. 120:1229–1239.

West, J. D., B. M. Voss, L. Pavliv, M. de Caestecker, A. R. Hemnes, and E. J. Carrier. 2016. Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload. Pulm Circ 6:211–223.

Zhang, W., A. L. Chancey, H. P. Tzeng, Z. Zhou, K. J. Lavine, F. Gao, et al. 2011. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 124:2106–2116.

Zhao, X. Y., L. Y. Zhao, Q. S. Zheng, J. L. Su, H. Guan, F. J. Shang, et al. 2008. Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol. Cell. Biochem. 310:159–166.